Skip to main content

Adding elotuzumab to lenalidomide/dexamethasone can prolong survival in relapsed/refractory myeloma

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Adding elotuzumab to lenalidomide/dexamethasone can prolong survival in relapsed/refractory myeloma

User login

Username

Password

Reset your password

Type	Lead	score